Euro Pacific Asset Management LLC Acquires 2,070 Shares of GSK plc (NYSE:GSK)

Euro Pacific Asset Management LLC boosted its holdings in GSK plc (NYSE:GSK) by 0.9% in the fourth quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor owned 234,116 shares of the pharmaceutical company’s stock after purchasing an additional 2,070 shares during the period. GSK comprises about 1.8% of Euro Pacific Asset Management LLC’s portfolio, making the stock its 27th largest holding. Euro Pacific Asset Management LLC’s holdings in GSK were worth $8,737,000 at the end of the most recent quarter.

Several other hedge funds and other institutional investors have also recently added to or reduced their stakes in the business. FinTrust Capital Advisors LLC grew its holdings in shares of GSK by 6.9% in the 3rd quarter. FinTrust Capital Advisors LLC now owns 4,346 shares of the pharmaceutical company’s stock valued at $158,000 after acquiring an additional 281 shares in the last quarter. UMB Bank n.a. grew its stake in GSK by 4.8% in the third quarter. UMB Bank n.a. now owns 6,462 shares of the pharmaceutical company’s stock valued at $234,000 after purchasing an additional 297 shares in the last quarter. Fiduciary Group LLC grew its stake in GSK by 3.3% in the first quarter. Fiduciary Group LLC now owns 9,367 shares of the pharmaceutical company’s stock valued at $342,000 after purchasing an additional 300 shares in the last quarter. KCS Wealth Advisory increased its position in shares of GSK by 1.5% during the 3rd quarter. KCS Wealth Advisory now owns 21,391 shares of the pharmaceutical company’s stock worth $775,000 after purchasing an additional 314 shares during the last quarter. Finally, BSW Wealth Partners raised its stake in shares of GSK by 5.2% during the 1st quarter. BSW Wealth Partners now owns 6,345 shares of the pharmaceutical company’s stock worth $226,000 after purchasing an additional 316 shares in the last quarter. 15.74% of the stock is currently owned by institutional investors and hedge funds.

GSK Stock Performance

GSK traded down $0.32 during trading hours on Thursday, reaching $39.28. The company’s stock had a trading volume of 1,022,048 shares, compared to its average volume of 3,484,873. The company’s 50-day moving average is $41.99 and its 200-day moving average is $38.76. GSK plc has a 52 week low of $33.33 and a 52 week high of $43.84. The firm has a market cap of $81.41 billion, a PE ratio of 13.16, a price-to-earnings-growth ratio of 1.83 and a beta of 0.64. The company has a debt-to-equity ratio of 1.19, a quick ratio of 0.62 and a current ratio of 0.88.

GSK (NYSE:GSK) last issued its quarterly earnings data on Wednesday, January 31st. The pharmaceutical company reported $0.72 earnings per share for the quarter, missing the consensus estimate of $0.76 by ($0.04). The company had revenue of $10 billion during the quarter, compared to the consensus estimate of $9.79 billion. GSK had a net margin of 16.24% and a return on equity of 51.45%. On average, equities analysts forecast that GSK plc will post 4.02 EPS for the current year.

GSK Increases Dividend

The company also recently declared a quarterly dividend, which was paid on Thursday, April 11th. Investors of record on Friday, February 23rd were issued a dividend of $0.3564 per share. This is a boost from GSK’s previous quarterly dividend of $0.34. This represents a $1.43 annualized dividend and a yield of 3.63%. The ex-dividend date of this dividend was Thursday, February 22nd. GSK’s dividend payout ratio (DPR) is presently 52.82%.

Wall Street Analyst Weigh In

GSK has been the subject of several analyst reports. Citigroup raised shares of GSK from a “neutral” rating to a “buy” rating in a research note on Tuesday, February 13th. Jefferies Financial Group raised shares of GSK from a “hold” rating to a “buy” rating in a research report on Wednesday, January 3rd. Morgan Stanley started coverage on shares of GSK in a report on Tuesday, January 23rd. They issued an “equal weight” rating on the stock. Finally, Guggenheim upgraded GSK from a “neutral” rating to a “buy” rating in a report on Monday, March 4th. One research analyst has rated the stock with a sell rating, one has given a hold rating, three have issued a buy rating and one has issued a strong buy rating to the company. According to MarketBeat, GSK presently has a consensus rating of “Moderate Buy”.

GSK Profile

GSK plc, together with its subsidiaries, engages in the research, development, and manufacture of vaccines, and specialty and general medicines to prevent and treat disease in the United Kingdom, the United States, and internationally. It operates through two segments, Commercial Operations and Total R&D.